Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

L-Arginine Supplements in Treating Women Who Are Cancer Survivors

This study has been completed.
Information provided by (Responsible Party):
Wake Forest Cancer Center CCOP Research Base Identifier:
First received: April 9, 2007
Last updated: March 15, 2013
Last verified: March 2013

RATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors.

PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.

Condition Intervention
Sexual Dysfunction
Sexuality and Reproductive Issues
Unspecified Adult Solid Tumor, Protocol Specific
Dietary Supplement: ArginMax
Dietary Supplement: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

Resource links provided by NLM:

Further study details as provided by Wake Forest Cancer Center CCOP Research Base:

Primary Outcome Measures:
  • Determine whether ArginMax improves the quality of life and sexual function. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Determine whether ArginMax improves the quality of life and sexual function for women cancer survivors by using the FACT-G and FSFI instruments.

Secondary Outcome Measures:
  • Quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    • Assess differences in quality of life between the two groups.
    • Determine differences in toxicity between the two groups.
    • Describe the sexual function symptom clusters (if any) in women cancer survivors.
    • To assess the effect of race on sexual function and quality of life.

Enrollment: 186
Study Start Date: May 2007
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I: ArginMax
ArginMax® (including placebo)
Dietary Supplement: ArginMax
Given orally
Other Name: L-arginine
Placebo Comparator: Arm II
Patients receive oral placebo twice daily
Dietary Supplement: placebo
Given orally

Detailed Description:



  • Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the quality of life and sexual function in female cancer survivors.


  • Compare quality of life of patients treated with ArginMax® vs placebo.
  • Compare toxicity of these regimens in these patients.
  • Describe the sexual function symptom clusters (if any) in these patients.

OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®) twice daily.
  • Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks for 12 weeks.

PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


Any female cancer survivor who identifies herself as concerned with her sexual quality of life and answering yes to all three of the screening questions.

  • Must express interest in sexual activity
  • At least 6 months following completion of all cancer therapy. Hormonal therapy and treatment with Herceptin are allowed.
  • No evidence of active cancer based on physical exam and/or radiographic images obtained within 3 months of study.
  • Absence of any mental, medical or physical disorder know to affect sexual function.
  • No participation in another study with an investigational study drug or device during the 30 days prior to start of study drug.
  • Lab values must meet the following criteria at study entry: WBC ≥ 2000, Hgb ≥ 10gm/dl, creatinine ≤ 1.5 x ULN, plt ≥ 100,000, T Bili ≤ 1.5
  • ECOG performance status must be 0-2.
  • Must be able to take oral medication
  • Must be 18 years old or older
  • Must be minority (non-white) female.


  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax.
  • Currently taking any blood thinner such as aspirin (one 81mg aspirin, or one baby aspirin per day allowed), Persantine, Heparin, Lovenox, or Coumadin (low dose Coumadin for catheter patency is allowed).
  • Patients currently taking Ginkgo Biloba are not allowed on this study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements and/or ability for sexual function.
  • Pregnant women are excluded from this study because ArginMax may be an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ArginMax, breastfeeding should be discontinued if the mother is treated with ArginMax.
  • Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with ArginMax. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.
  • Any planned surgery during study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00459134

  Show 25 Study Locations
Sponsors and Collaborators
Wake Forest Cancer Center CCOP Research Base
Principal Investigator: Kathryn M. Greven, MD Wake Forest Cancer Center CCOP Research Base
  More Information

Additional Information:
No publications provided

Responsible Party: Wake Forest Cancer Center CCOP Research Base Identifier: NCT00459134     History of Changes
Other Study ID Numbers: CCCWFU 97106, U10CA081851
Study First Received: April 9, 2007
Last Updated: March 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Wake Forest Cancer Center CCOP Research Base:
sexual dysfunction
sexuality and reproductive issues
unspecified adult solid tumor, protocol specific processed this record on November 23, 2014